3 Drugs Stocks On The Rise

TheStreet highlights 3 stocks pushing the drugs industry higher today.
By TheStreet Wire ,

All three major indices are trading down today with the

Dow Jones Industrial Average

(

^DJI

) trading down 11 points (-0.1%) at 17,856 as of Thursday, Nov. 5, 2015, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,091 issues advancing vs. 1,846 declining with 161 unchanged.

The Drugs industry currently sits down 1.3% versus the S&P 500, which is down 0.3%. On the negative front, top decliners within the industry include

bluebird bio

(

BLUE

), down 20.4%,

Valeant Pharmaceuticals International

(

VRX

), down 11.7%,

Celgene

(

CELG

), down 5.7%,

Gilead

(

GILD

), down 2.1% and

Vertex Pharmaceuticals

(

VRTX

), down 2.0%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3.

AstraZeneca

(

AZN

) is one of the companies pushing the Drugs industry higher today. As of noon trading, AstraZeneca is up $0.32 (1.0%) to $32.45 on average volume. Thus far, 1.4 million shares of AstraZeneca exchanged hands as compared to its average daily volume of 2.5 million shares. The stock has ranged in price between $32.39-$32.78 after having opened the day at $32.78 as compared to the previous trading day's close of $32.13.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. AstraZeneca has a market cap of $81.7 billion and is part of the health care sector. Shares are down 8.7% year-to-date as of the close of trading on Wednesday. Currently there are 3 analysts who rate AstraZeneca a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates

AstraZeneca

as a

hold

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself, disappointing return on equity and weak operating cash flow. Get the full

AstraZeneca Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Novo Nordisk A/S

(

NVO

) is up $1.39 (2.6%) to $54.98 on heavy volume. Thus far, 1.3 million shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $54.75-$56.09 after having opened the day at $56.03 as compared to the previous trading day's close of $53.59.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $143.8 billion and is part of the health care sector. Shares are up 26.6% year-to-date as of the close of trading on Wednesday. Currently there are 2 analysts who rate Novo Nordisk A/S a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates

Novo Nordisk A/S

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, notable return on equity, expanding profit margins and increase in net income. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Novo Nordisk A/S Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Allergan

(

AGN

) is up $3.01 (1.0%) to $310.68 on light volume. Thus far, 1.3 million shares of Allergan exchanged hands as compared to its average daily volume of 4.2 million shares. The stock has ranged in price between $305.01-$312.00 after having opened the day at $308.59 as compared to the previous trading day's close of $307.67.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Allergan plc develops, manufactures, and distributes generic, branded, biosimilar, and over-the-counter (OTC) pharmaceutical products. It operates in three segments: North American Brands, North American Generics and International, and Anda Distribution. Allergan has a market cap of $121.8 billion and is part of the health care sector. Shares are up 19.5% year-to-date as of the close of trading on Wednesday. Currently there are 13 analysts who rate Allergan a buy, 1 analyst rates it a sell, and none rate it a hold.

TheStreet Ratings rates

Allergan

as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. Get the full

Allergan Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

Loading ...